Furthermore, special attention should be paid to one patient in our study who developed TEN and ultimately died after receiving the PD-1/CTLA-4 bispecific antibody (Ipilimumab-Tovoralimab, as presented in Table 1). This evidence concerns the gene PDCD1 and toxic epidermal necrolysis.